Investors Getting Picky When It Comes To Buying Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (NASDAQ:BEAM) does about 1.53M shares in volume on a normal day but saw 1240740 shares change hands in Friday’s trading. The company now has a market cap of 1.75B USD. Its current market price is $21.26, marking a decrease of -5.68% compared to the previous close of $22.54. The 52 week high reached by this stock is $49.50 whilst the lowest price level in 52 weeks is $16.95.

Beam Therapeutics Inc (BEAM) has a 20-day trading average at $22.97 and the current price is -57.05% off the 52-week high compared with 25.43% distance from its 52-week low. The 50-day simple moving average of the closing price is $29.27 and its 200-day simple moving average is $26.84. If we look at the stock’s price movements over the week, volatility stands at 5.02%, which increases to 5.61% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 30.80 to suggest the stock is neutral.

The consensus objective for the share price is $48.38, suggesting that the stock has a potential upside of 56.06% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 29, 2024 when JP Morgan upgraded the stock to “Overweight” and issued a price target of between $38 and $40. BofA Securities downgraded the stock to “Neutral” from Buy on December 15, 2023 at a price target of $35. Jefferies downgraded its price target at $75-$30.

Beam Therapeutics Inc (BEAM) stock is down -8.08% over the week and -22.04% over the past month. Its price is -21.90% year-to-date and -40.70% over the past year.

To reach the target analysts have set, the stock logically needs to grow 56.06 percent from here.

The company has a return on investment of -12.60% and return on equity of -16.09%. The beta has a value of 1.88. Price to book ratio is 1.91 and price to sales ratio is 4.85.